うつ病のNH102を評価する第II相研究 (NH102-21)
うつ病の治療におけるNH102の有効性と安全性を評価するための、多施設、無作為化、二重盲検、プラセボ、活性コントロール、用量拡張第IIフェーズII臨床試験
This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.
調査の概要
状態
条件
詳細な説明
This trial consists of three periods: a screening period (up to 2 weeks), a double-blind treatment period (6 weeks), and a tapering-off period/safety follow-up (1 week). The screening period may last up to 14 days and a minimum of 1 day.
Baseline assessments will be conducted prior to randomization to confirm the eligibility of participants. A total of 240 patients with depression will be randomly assigned in a 1:1:1:1:1 ratio to three experimental drug groups (10 mg, 20 mg, and 30 mg), one active control group (duloxetine hydrochloride capsules 60 mg ), or one placebo group. The double-blind treatment period will last for 6 weeks, during which participants will take the assigned medications according to the specified dosing regimen and will be followed up at the end of weeks 1, 2, 4, and 6. After the treatment period, participants will enter a 1-week tapering-off period and will undergo safety follow-up at the end of week 7.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Anhui
-
Hefei、Anhui、中国、230000
- Anhui Mental Health Center
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100096
- Beijing Huilongguan Hospital
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400036
- Chongqing Mental Health Center
-
-
Fujian
-
Xiamen、Fujian、中国、361012
- Xiamen Xianyue Hospital
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510370
- The Affiliated Brain Hospital of Guangzhou Medical University
-
Shenzhen、Guangdong、中国、518118
- Shenzhen Kangning Hospital
-
-
Hebei
-
Baoding、Hebei、中国、071000
- Hebei Mental Health Hospital
-
-
Henan
-
Xinxiang、Henan、中国、453000
- The Second Affiliated Hospital of Henan Medical University
-
Zhumadian、Henan、中国、463000
- Zhumadian Second People's Hospital
-
-
Hunan
-
Changsha、Hunan、中国、410007
- Hunan Second people's Hospital
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215000
- Suzhou Guangji Hospital
-
Wuxi、Jiangsu、中国、214000
- Wuxi Mental Health Center
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330038
- Nanchang Mental Health Center
-
-
Jilin
-
Siping、Jilin、中国、136000
- Jilin Provincial Neuropsychiatric Hospital
-
-
Shandong
-
Jinan、Shandong、中国、250014
- Shongdong Mental Health Center
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200030
- Shanghai Mental Health Center
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030000
- Frist Hospital of Shanxi Medical University
-
Xi’an、Shanxi、中国、710000
- Xi'an Mental Health Center
-
-
Sichuan
-
Chengdu、Sichuan、中国、610072
- Sichuan Provincial People's Hospital
-
Chengdu、Sichuan、中国、610000
- The Fourth People's Hospital of Chengdu
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300000
- Tianjin Anding Hospital
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310003
- Hangzhou Seventh People's Hospital
-
Huzhou、Zhejiang、中国、313000
- Huzhou Third Municipal Hospital
-
Ningbo、Zhejiang、中国、315000
- The Affiliated Kangning Hospital of Ningbo University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male and female outpatients aged 18-65 years (inclusive).
- Diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria ( without psychotic features).
- Hamilton Depression Rating Scale (HAM-D17) total score ≥ 22 at screening and baseline visits, with item 1 (depressed mood) score ≥ 2.
- Clinical Global Impression-Severity (CGI-S) score ≥ 4 at screening and baseline.
- Negative pregnancy test for women of childbearing potential.
- Willingness to use effective contraception during the trial and for 3 months after the last dose.
- Voluntary participation and signed informed consent.
Exclusion Criteria:
- Duration of the current depressive episode in first-episode patients < 3 months.
- Treatment-resistant depression (failure of ≥ 2 adequate antidepressant treatments).
- Other psychiatric disorders (e.g., schizophrenia, bipolar disorder, anxiety disorders).
- History of severe neurological diseases, epilepsy, or significant head trauma.
- Unstable or severe cardiovascular, gastrointestinal, or endocrine diseases.
- History of malignancy within the past 2 years.
- History of increased intraocular pressure or untreated narrow-angle glaucoma.
- Abnormal thyroid function not adequately controlled.
- History of severe drug allergies or hypersensitivity to duloxetine or excipients.
- Suicide attempt within the past year or significant suicide risk.
- Substance abuse within the past year or positive at screening drug test.
- Alcohol abuse (≥ 14 units/week) within the past year.
- Previous treatment with duloxetine without adequate response.
- Normative use of antidepressants within 2 weeks prior to screening.
- Use of CYP2D6 or CYP1A2 potent inhibitors/inducers within 2 weeks prior to screening.
- Participation in another clinical trial within the past 3 months.
- Any condition deemed unsuitable by the investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ
|
Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period. |
|
実験的:NH102 10mg
|
5 mg twice daily over 6 weeks, followed by a 1-week tapering period. 10 mg twice daily over 6 weeks, followed by a 1-week tapering period. 15 mg twice daily over 6 weeks, followed by a 1-week tapering period. |
|
実験的:NH102 20mg
|
5 mg twice daily over 6 weeks, followed by a 1-week tapering period. 10 mg twice daily over 6 weeks, followed by a 1-week tapering period. 15 mg twice daily over 6 weeks, followed by a 1-week tapering period. |
|
実験的:NH102 30mg
|
5 mg twice daily over 6 weeks, followed by a 1-week tapering period. 10 mg twice daily over 6 weeks, followed by a 1-week tapering period. 15 mg twice daily over 6 weeks, followed by a 1-week tapering period. |
|
アクティブコンパレータ:デュロキセチン塩酸塩腸カプセル
|
30 mg twice daily for 6 weeks, followed by a 1-week tapering period. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
17 items Hamilton Depression Scales (HAM-D17)
時間枠:6 Weeks
|
Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at the end of treatment. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome. |
6 Weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
17 items Hamilton Depression Scales (HAM-D17)
時間枠:Week 2 and 4
|
Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at Week 2 and 4. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome. |
Week 2 and 4
|
|
Montgomery- Åsberg Depression Rating Scale(MADRS)
時間枠:6 Weeks
|
Changes from baseline in the 10-items Montgomery- Åsberg Depression Scales (MADRS) total score at Week 2, Week 4 and the end of treatment. MADRS is a standardized, clinician-administered rating scale that assesses 10 items characteristically associated with major depression. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). |
6 Weeks
|
|
Clinical Global Impression-Improvement (CGI-I)
時間枠:6 Weeks
|
Changes from baseline in the CGI-I score at the end of treatment. The Clinical Global Impression-Improvement (CGI-I) scale is a clinician-rated instrument designed to assess the overall improvement or worsening of a patient's condition relative to a baseline state. The following one query is rated on a seven-point scale: "Compared to the patient's condition at admission to the project, this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment." |
6 Weeks
|
|
Clinical Global Impression-Severity (CGI-S)
時間枠:6 Weeks
|
Changes from baseline in the Clinical Global Impression-Severity (CGI-S) score at the end of treatment. The CGI-S asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. |
6 Weeks
|
|
Hamilton Anxiety Rating Scale (HAM-A)
時間枠:6 Weeks
|
Changes from baseline in the HAM-A total score at the end of treatment. The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered assessment tool to measure the severity of anxiety symptoms. It consists of 14 items, each evaluating a specific symptom of anxiety, such as anxious mood, tension, fears, and somatic complaints. Each item is scored on a scale from 0 (None) to 4 ( Very severe. grossly disabling ), with the total score ranging from a minimum of 0 to a maximum of 56. Higher scores indicate greater severity of anxiety symptoms, reflecting a worse clinical outcome. |
6 Weeks
|
|
Dimensional Anhedonia Rating Scale (DARS)
時間枠:6 Weeks
|
Change from baseline in Dimensional Anhedonia Rating Scale (DARS) total score at the end of treatment. The DARS is a self-report scale that measures anhedonia across the following 4 domains: hobbies/past-times, food/drinks, social activities, and sensory experiences. Within each domain, participants are required to provide at least two of their own examples of what they find rewarding. Subsequently, participants answer a set of standardized questions about desire, motivation, effort and consummatory pleasure for the examples provided. Responses were based on a 5-point Likert scale (Not at all=0; Slightly=1; Moderately=2; Mostly=3; Very Much=4), with the total score ranging from a minimum of 0 to a maximum of 68. A higher score reflects a better outcome. |
6 Weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NH102-21
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。